Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that for thyroid cancer patients who underwent radical mastectomy, the combination of CAF regimen and fufangbanmao capsule improved short-term clinical efficacy, enhanced immune function, reduced drug toxicity, and positively impacted quality of life compared to the CAF regimen alone.

This study found that a mitoxantrone, vincristine, and prednisolone regimen effectively treated recurrent breast cancer with a 70% response rate, though it was associated with significant myelosuppression.

In this study, among Indian patients with triple-negative breast cancer, Ki-67 expression levels were high but not significantly associated with treatment response to a neoadjuvant docetaxel-carboplatin regimen, which showed complete clinical, imaging, and pathological response rates of 39.13%, 34.78%, and 47.61%, respectively.

In this study, all patients receiving chemotherapy for breast carcinoma experienced chemotoxicities like hair loss, nausea, and fatigue, with no one regimen identified as more toxic than another.

In this study, scalp hypothermia with the Theracool™ cooling machine was largely ineffective for preventing alopecia in breast cancer patients undergoing a chemotherapeutic regimen including cyclophosphamide and anthracyclines.

In this study, scalp cooling therapy was found to be well tolerated and effective at improving hair preservation for Asian women with breast or gynecological cancers undergoing certain chemotherapy regimens, particularly weekly paclitaxel, compared to historical controls.

This scoping review found that chemotherapy-induced alopecia in breast cancer patients, especially when using anthracycline- and taxane-based regimens, occurs at higher rates and with more persistence than historically reported.

This study developed caffeine-loaded nanoparticles coated with ultradeformable liposomes for better hair follicle delivery, showing non-cytotoxicity and potential to reduce oxidative stress in DHT-damaged cells, suggesting an alternative treatment for androgenetic alopecia.

This source provides medical information intended solely for licensed professionals and emphasizes that it is not a substitute for medical advice, diagnosis, or treatment decisions, which remain the responsibility of treating physicians.

Vitamin D3 may prevent hair loss from chemotherapy, but side effects and cancer cell protection are concerns.

In this noninferiority study, researchers found that a 0.2% caffeine-based topical liquid was not less effective than 5% minoxidil solution in improving hair growth in men with androgenetic alopecia over six months.

This research highlights that engineered mice lacking the vitamin D receptor show multiple health issues similar to human vitamin D deficiency, underscoring the widespread impacts of the vitamin D endocrine system.

This study found that in female breast cancer patients, supplementation with 400 mg IND02 (Cinnamon bark extract) thrice daily during chemotherapy significantly reduced severe weight loss and hair loss compared to placebo, with the treatment being well-tolerated and safe.

This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.

This study found that adjuvant docetaxel treatment for breast cancer at cumulative doses of 400 mg/m² or higher is associated with a 10% prevalence of persistent alopecia leading to wig use, but this was completely prevented with scalp cooling.

This study examines the development and application of cultured models for gallbladder carcinoma and highlights innovations and challenges in constructing effective in vitro growth models for cancer research.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

This review highlights various alternative and complementary treatments for androgenic alopecia, noting that while only two FDA-approved options exist, increased awareness among dermatologists of supportive evidence for other therapies may better inform patient education.

This review summarizes various effects of bergamot components on multiple health conditions in humans and animals but reports limitations in their use for stress and anxiety relief in aromatherapy.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

This review discusses botulinum toxin's experimental off-label uses in dermatology, highlighting promising results but emphasizing the need for more clinical trials to confirm efficacy and safety.

This article discusses the emotional and psychological impact of severe alopecia areata on patients, emphasizing feelings of loss, vulnerability, and self-identity changes, and reports no new results.

This review covers dermatological conditions experienced by ice-skating athletes due to cold exposure, infections, and inflammation, providing no new clinical findings and emphasizing diagnosis and treatment strategies.

This review discusses the enhanced permeability and retention (EPR) effect as a mechanism for targeted drug delivery in cancer therapy and reports no new clinical results.

This review discusses the pathophysiology, diagnosis, and management of functional hypothalamic amenorrhea in adolescent girls and reports no new clinical results.

This review discusses the perimenopause, its symptoms, and management options, emphasizing the role of pharmacists in educating and advising women on treatment strategies and preventive health measures, but it reports no new results.

This review discusses the efficacy and safety of exemestane as a treatment for estrogen-receptor-positive breast cancer and reports no new clinical results.

Cosmeceuticals may benefit skin health but need more research for efficacy and safety confirmation.

Both photobiomodulation and low-frequency treatments effectively reduce body measurements.